Abstract
Background Changes to sleep, weight, and endocrine function are common in Alzheimer’s disease (AD) and Lewy-body dementia (LBD). The cause of these is not known, but they may be related to hypothalamic neurodegeneration.
Methods We performed a systematic search of MEDLINE and EMBASE of studies using structural magnetic resonance imaging to examine hypothalamic volume in people with AD or LBD. The Newcastle-Ottawa scale was used to assess the risk of bias. A random-effects meta-analysis was conducted using the standardised mean difference (SMD) in hypothalamic volume as the effect measure, and a narrative synthesis was used to examine the relationship between hypothalamic volume and sleep, eating, and endocrine function.
Results We identified 6542 articles which resulted in 12 included studies, most which had a low to moderate risk of bias. The meta-analysis included 454 people with mild-moderate AD (Mini-Mental State (MMSE) range: 19.2-26.1) and 715 controls. We found that people with AD had a significantly smaller hypothalamus (pooled SMD: -0.49, t=-3.47, p=0.018, 95%CI: -0.86 to - 0.13). There was significant heterogeneity of a moderate degree (Tau2=0.0665, 95%CI:0.005-0.8090; I2=67%, 95%CI:21.5%-86.1%; Q=15.16, p<0.01), but no evidence of publication bias. Only one study examined people with LBD, finding qualitative evidence of lower hypothalamic volume compared to controls. Hypothalamic volume loss in AD was more marked in men and may be associated with plasma levels of sex hormones and decreased bone mineral density.
Conclusion Reduced hypothalamic volume is seen early in AD and LBD and this may influence endocrine function. A better understanding of hypothalamic degeneration in dementia may help elucidate how pathology relates to symptoms in AD and LBD and reveal new targets for intervention.
Competing Interest Statement
AASL's post is funded by a grant from Altos labs and is a member of the National Institute for Health and Care Research (NIHR) Dementia Portfolio Development Group. This research was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson's Plus Disorders. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Data from this project will also be included as part of a PhD thesis by AASL. BRU is the R&D director at his trust, CRN lead for dementia for the East of England and national CRN lead for stratified medicine in dementia. He is the vice-chair of the faculty of old age psychiatry in the Royal College of Psychiatry. His post is part funded by a generous donation from Gnodde Goldman Sachs gives. He has served in a paid role on an advisory boards for Lilly and TauRx.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024547743
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
8.0 Data availability
Data is available from the corresponding author upon reasonable request.
